Related Experiment Video
Updated: Jan 20, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Antivirals and vaccines for Enterovirus A71
Jing-Yi Lin1, Yu-An Kung2, Shin-Ru Shih3,4,5,6
1Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei City, Taiwan.
Abstract:
Enterovirus A71 (EV-A71) is an important emerging virus posing a threat to children under five years old. EV-A71 infection in infants or young children can cause hand-foot-and-mouth disease, herpangina, or severe neurological complications. However, there are still no effective antivirals for treatment of these infections. In this review, we summarize the antiviral compounds developed to date based on various targets of the EV-A71 life cycle. Moreover, development of a vaccine would be the most effective approach to prevent EV-A71 infection. Therefore, we also summarize the development and clinical progress of various candidate EV-A71 vaccines, including inactivated whole virus, recombinant VP1 protein, synthetic peptides, viral-like particles, and live attenuated vaccines.
Related Concept Videos
Vaccinations
12:02Assays for the Identification of Novel Antivirals against Bluetongue Virus
09:04In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
06:17Expression and Purification of Virus-like Particles for Vaccination
02:48Determining Antiviral Efficacy of Experimental Drugs Through a Plaque Assay
12:32EPA Method 1615. Measurement of Enterovirus and Norovirus Occurrence in Water by Culture and RT-qPCR. Part III. Virus Detection by RT-qPCR
